Buy Cozaar (Losartan) Online — Merck FIRST Angiotensin II Receptor Blocker (ARB) for Hypertension, Diabetic Nephropathy & Stroke Risk Reduction in LVH

🕓 Three Decades of Losartan — From Discovery to Landmark Trial Programme

🎯 Where Losartan Earns Deliberate Choice

🔬 LOSARTAN — FOUR DEFINING FEATURES

Each feature is explored in detail in sections 2, 3, 8, and 19.

🧭 Reader Navigation — Jump to What Matters for You

• First prescription and titration: sections 9, 11
• LIFE trial and HTN with LVH: section 6
• RENAAL trial and diabetic nephropathy: section 7
• Uric acid lowering and gouty hypertension: sections 8, 24
• ACE cough switch to ARB: section 12
• Once vs twice daily dosing question: section 15
• CYP2C9 pharmacogenetics: section 19
• Switching between ARBs: section 26

💊 Losartan Pharmacokinetics at a Glance

The Shortest ARB Half-Life — Practical Consequences

Losartan's combined parent-plus-metabolite pharmacological cover is shorter than any other clinically-used ARB. This has two practical consequences:

• Trough-to-peak BP ratio is lower than for irbesartan, telmisartan, or candesartan — the 24-hour cover is less smooth
• Twice-daily dosing is sometimes needed for smooth 24-hour BP control, particularly at lower doses

The CYP2C9 Consideration

Approximately 3-5% of Caucasian populations are CYP2C9 poor metabolisers who cannot efficiently convert losartan to E-3174. These patients have reduced antihypertensive response to losartan and may need higher doses or an alternative ARB. Section 19 covers the pharmacogenetics in detail.

🧬 What AT1 Receptor Blockade Does

Why Losartan Does Not Cause the ACE Cough

ACE inhibitors block the enzyme that produces angiotensin II AND breaks down bradykinin. Blocking ACE causes bradykinin accumulation, which sensitises the airway cough reflex. Losartan acts downstream of ACE at the AT1 receptor — bradykinin metabolism is unaffected. This is why ARB cough incidence is comparable to placebo, and why the ACE-to-ARB switch resolves cough in the 15-20% of ACE inhibitor users who develop it.

The URAT1 Uric Acid Mechanism

Losartan (parent, not E-3174) inhibits URAT1 — a transporter in renal proximal tubules that reabsorbs urate from the filtrate. Blocking URAT1 causes more urate to be excreted in urine and less to accumulate in blood. The effect is modest (approximately 15% reduction in serum uric acid) but genuine. No other ARB has this property. Section 8 explores the practical implications.

🔬 Where Losartan Sits Among ARBs

A Practical Note on ARB Choice in 2026

Since patent expiry, losartan has become one of the least expensive ARBs. In many formularies it is the default first-choice ARB simply because of cost, with switches to another ARB reserved for specific reasons (inadequate control, side effects, HFrEF where candesartan or valsartan is preferred). This is a legitimate approach given the substantial class overlap in efficacy.

Losartan Position in Modern Hypertension Guidelines

Modern hypertension guidelines list ARBs including losartan as one of the four preferred first-line antihypertensive classes. Losartan is often chosen as the ARB simply because of its cost profile since patent expiry — the class effect is largely shared, and losartan is a legitimate first-choice ARB unless specific reasons favour a different agent.

🏆 LIFE Trial at a Glance

What LIFE Established

• Losartan superior to atenolol at equivalent BP reduction in HTN with LVH
• Not a BP effect — both arms achieved same BP; benefit was drug-specific
• Stroke reduction was the strongest signal (25% reduction)
• Contributed to guideline change demoting beta blockers as first-line antihypertensives
• Established LVH regression benefit with ARB therapy

Dr Alvarado-Escalona on LIFE and modern practice

"LIFE was one of the trials that reshaped how we think about hypertension pharmacotherapy. The finding that ARB was superior to beta blocker at equivalent BP reduction, specifically in patients with LV hypertrophy, contributed to the wider evidence base that led to beta blocker demotion as first-line for uncomplicated hypertension. In our cardiological practice in Honduras, losartan retains a specific place in hypertensive patients with echocardiographic evidence of LV hypertrophy — the LIFE trial specifically supports this indication. For general hypertension without LVH, any ARB or ACE inhibitor is appropriate first-line, and losartan is often chosen simply because it is inexpensive and well-tolerated."

Tomas J. Alvarado-Escalona, MD, MSc — Department of Cardiology, Hospital Escuela Universitario, Universidad Nacional Autonoma de Honduras

🩸 RENAAL Trial at a Glance

RENAAL vs IDNT — The Two T2DM Nephropathy ARB Trials

RENAAL (losartan) and IDNT (irbesartan) both examined T2DM overt nephropathy and both showed reno-protective benefit. They differed:

• RENAAL: losartan 50-100 mg; 16% reduction in composite renal endpoint; 25% reduction in creatinine doubling
• IDNT: irbesartan 300 mg; 20% reduction in composite; comparison against amlodipine included
• Practical implication: either drug is a legitimate first-choice ARB in T2DM overt nephropathy; guideline endorsement is roughly equal

Dr Merchant-Mahomedali on RENAAL and diabetic nephropathy practice

"RENAAL and IDNT together established the specific reno-protective role of ARB therapy in T2DM patients with overt nephropathy. In our nephrology practice at Aga Khan Karachi, we frequently see this exact patient population — South Asian T2DM with proteinuric CKD — and losartan is our commonest first-choice ARB because of the RENAAL evidence and the very favourable generic pricing. The 100 mg dose used in RENAAL is the target we aim for in this specific population; the 50 mg antihypertensive dose is not the reno-protective target. This distinction matters for real-world outcomes."

Kausar B. Merchant-Mahomedali, MBBS, MRCP (UK), FRCP — Section of Nephrology, Aga Khan University Hospital Karachi

🪴 The Uric Acid Lowering Mechanism

Mechanistically:

• URAT1 (urate transporter 1) is expressed on renal proximal tubule brush border membrane
• Normally reabsorbs about 90% of filtered urate back into blood
• Losartan (parent molecule, not E-3174) inhibits URAT1, so less urate is reabsorbed
• Net effect: approximately 15% reduction in serum uric acid

Note: this is a losartan-specific effect. Other ARBs, and E-3174 itself, do not inhibit URAT1.

Practical Clinical Implications

• Modest effect size: approximately 15% reduction in serum uric acid — not enough to treat symptomatic gout alone
• Deliberate choice in gouty hypertensives: losartan provides BP control PLUS modest uric acid reduction, whereas most ARBs (and especially thiazides) worsen uric acid
• Not a substitute for allopurinol in patients with symptomatic gout requiring urate-lowering therapy
• Useful in hyperuricaemic hypertensive without symptomatic gout — combined BP and uric acid benefit

Dr Cordeiro-Aguiar on losartan in gouty practice

"In our rheumatology practice at UFRJ, losartan is often the ARB we recommend when a hypertensive patient has concurrent hyperuricaemia or symptomatic gout. Not because losartan is a gout treatment — it is not, and allopurinol remains the standard urate-lowering therapy — but because it does not aggravate uric acid the way thiazides do and it may modestly reduce it. In our experience, using losartan alongside allopurinol makes achieving target uric acid slightly easier, and the choice of losartan over another ARB in this specific patient population is a small but genuine advantage. The framing to patients is important: losartan will not fix the gout, but it will not make it worse and may help a little."

Manuela V. Cordeiro-Aguiar, MD, PhD — Rheumatology Service, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro

📆 Titration for Essential Hypertension

1. Start: 50 mg once daily in the morning (25 mg if elderly, volume-depleted, or on diuretic)
2. Review at 2-4 weeks: home BP, potassium, creatinine, tolerance
3. Titrate up if BP not at target: 100 mg once daily — OR — 50 mg twice daily for smoother 24-hour cover
4. Combine if not at target on 100 mg: add hydrochlorothiazide 12.5-25 mg (fixed-dose Hyzaar exists) or amlodipine

Titration for Trial-Supported Indications

• HTN with LVH (LIFE): target 100 mg once daily — the trial dose associated with stroke reduction benefit
• T2DM overt nephropathy (RENAAL): target 100 mg once daily — the trial dose associated with reno-protection
• Starting doses same: 50 mg once daily, titrating to 100 mg over 2-4 weeks

Once vs Twice Daily — The Practical Question

Because losartan's pharmacological cover is shorter than most other ARBs, some patients need 50 mg twice daily rather than 100 mg once daily for smooth 24-hour BP control. Home BP data (morning trough vs afternoon effect) guides the decision. Section 15 explores this in detail.

The Fluconazole Interaction — A Losartan-Specific Concern

Because losartan requires CYP2C9 activation, strong CYP2C9 inhibitors (fluconazole is the most common example) can reduce the antihypertensive effect. During a fluconazole course, BP effect may be transiently reduced; this usually settles a week after the antifungal is finished. If BP control matters during the fluconazole course, monitoring or bridging with a different antihypertensive is worth considering.

🚩 PATIENTS AT ELEVATED FIRST-DOSE HYPOTENSION RISK

• Patients on diuretics — particularly loop or high-dose thiazide
• Patients with heart failure — particularly recently diuresed
• Elderly patients — slower baroreflex
• Severe hyponatraemia (Na below 130 mmol/L)
• Volume depletion from any cause

▶️ Practical Initiation Measures

First-Prescription Counselling

Every patient starting losartan should be told: pregnancy must be reported immediately (boxed warning); any facial swelling requires emergency care (angioedema); the drug can be stopped abruptly if needed (no rebound like beta blockers); if switched from ACE inhibitor for cough, the cough should resolve within 1-2 weeks confirming the switch was appropriate.

🌬️ Why Losartan Does Not Cause the ACE Cough

ACE inhibitors block the enzyme that both produces angiotensin II AND breaks down bradykinin. Blocking ACE causes bradykinin accumulation, which sensitises the airway cough reflex in susceptible individuals. Losartan acts downstream of ACE at the AT1 receptor — bradykinin metabolism is unaffected.

• ACE cough incidence: 15-20% of ACE inhibitor users
• Losartan cough incidence: ~3% — comparable to placebo
• Bradykinin metabolism: unchanged with ARBs

The Standard ACE Cough Switch to Losartan

1. Stop the ACE inhibitor
2. Wait 1-2 weeks for the cough to resolve (this confirms attribution to the ACE inhibitor)
3. Start losartan 50 mg once daily
4. Titrate to BP target (usually 50-100 mg)
5. The cough usually does not recur on losartan

Why Losartan Is Often the First-Tried ARB

Since patent expiry, losartan is one of the least expensive ARBs. When a patient develops ACE cough and needs an ARB, formulary considerations often push losartan as the first choice. If BP control is inadequate at 100 mg or twice-daily 50 mg, a switch to a longer-half-life ARB (candesartan, irbesartan, telmisartan) is a legitimate second step.

🚩 ANGIOEDEMA — STOP COZAAR AND SEEK EMERGENCY CARE

• Swelling of the lips, tongue, or throat
• Difficulty breathing or swallowing
• Change in voice or hoarseness
• Painless swelling of the face without a rash
• Sudden severe abdominal pain with visceral swelling (rare)

Airway involvement is a medical emergency. Once losartan angioedema has occurred, no ARB or ACE inhibitor is safe to restart.

Prior ACE Inhibitor Angioedema — The Losartan Question

Patients with prior ACE inhibitor angioedema have 3-10% cross-reactivity risk with ARBs including losartan. Where the RAAS blockade benefit is substantial (HFrEF, diabetic nephropathy), losartan may be considered under specialist input with clear counselling on emergency signs. Where alternatives are equivalent (essential hypertension), switching to a non-RAAS class is often the safer choice.

When Does Angioedema Occur?

ARB angioedema can appear at any point — days after starting, months, or years into use. Late-onset angioedema in patients tolerating losartan for years without issue is possible. This is why patient counselling emphasises the specific warning signs regardless of how long they have been on the drug.

🍌 Risk Factors That Raise Hyperkalaemia Probability

• Reduced kidney function — eGFR below 60, more so below 30
• Diabetes, particularly with nephropathy
• Potassium-sparing diuretics (spironolactone, eplerenone, amiloride)
• Chronic NSAIDs
• Trimethoprim / cotrimoxazole
• Potassium supplements or low-sodium salt substitutes

Potassium Monitoring on Losartan

Response to Rising Potassium

Modest rise (up to 5.5 mmol/L in a stable patient without contributor) may need only closer monitoring. Higher values with new contributor usually respond to removing the contributor rather than stopping losartan. Above 6.0 with cause, dose reduction or potassium binder consideration. Above 6.5 warrants urgent management.

🩺 Practical Home BP Routine on Losartan

1. Standard technique: seated 5 minutes, feet flat, arm at heart level, cuff on bare skin
2. Two readings a minute apart at each measurement
3. Morning trough before medication (represents lowest daily effect)
4. Peak reading 3-6 hours after morning dose (represents strongest effect)
5. Weekly log before office review

Once Daily vs Twice Daily — When to Switch

Signs that a losartan patient would benefit from twice-daily dosing:

• Morning trough BP consistently high despite acceptable evening/afternoon readings
• Trough-to-peak BP difference over 15 mmHg systolic
• Rebound morning BP surge particularly at low dose (25-50 mg once daily)
• Better home BP control on 50 mg twice daily than 100 mg once daily at total dose equivalence

Home BP Target Ranges

General hypertension: home average under 135/85 mmHg. Diabetes or CKD with albuminuria (RENAAL population): home average under 125/75 mmHg. Post-stroke: under 125/75 mmHg. HTN with LVH (LIFE): under 135/85 mmHg with LVH regression as secondary marker.

✅ The Expected Small Creatinine Rise

A 10-15% rise in serum creatinine in the first 2-4 weeks after starting losartan is expected and reflects the reno-protective haemodynamic mechanism working — not kidney damage. The rise stabilises at the new level.

A rise above 30% from baseline warrants investigation: dehydration, added NSAID, or undiagnosed renovascular disease.

Renovascular Disease Considerations

Bilateral renal artery stenosis or unilateral stenosis in a single functioning kidney is a contraindication. Any unexplained doubling of creatinine after starting losartan warrants consideration of undiagnosed renovascular disease.

🩹 Common Losartan Side Effects with Expected Trajectory

Where Losartan's Profile Is Favourable

No characteristic ACE cough (ARB class advantage); much lower angioedema than ACE inhibitors; unique modest uric acid lowering effect; no bronchospasm concern; effective without triggering reflex tachycardia; extensive real-world experience over 30 years; among least expensive antihypertensives worldwide. These are the reasons losartan remains one of the most-prescribed ARBs.

❤️ Losartan in HF and Post-MI Care

If Losartan Is Used in HFrEF

• Combine with the four pillars: beta blocker, MRA, SGLT2 inhibitor
• Target 100-150 mg per day (split BID often used)
• Consider switch to ARNI (sacubitril/valsartan) if affordable — better mortality evidence in HFrEF
• 36-hour washout if transitioning to ARNI

🧬 CYP2C9 Metaboliser Status Distribution

Clinical Implication in Practice

Pharmacogenomic testing for CYP2C9 status is not routine before losartan prescription. In practice, poor metaboliser status is inferred rather than tested:

• Suspect poor metaboliser status if losartan 100 mg produces inadequate BP response despite good adherence and no interacting drugs
• Practical response: switch to a non-prodrug ARB (irbesartan or olmesartan) which does not require activation
• Alternative: switch to a different antihypertensive class

Drugs That Mimic Poor Metaboliser Status

Strong CYP2C9 inhibitors (particularly fluconazole) transiently produce the same phenotype as poor metaboliser status — reduced E-3174 formation and blunted losartan effect. During a fluconazole course, BP may drift up; monitoring or bridging with a different antihypertensive is worth considering.

⏰ What to Do About a Missed Dose

Missed Dose on Twice-Daily Losartan

If on losartan 50 mg BID and morning dose missed by less than 4 hours, take it and stay on schedule. If more than 4 hours late (so within 8 hours of evening dose), skip morning and take evening at usual time.

Doubling Up Is Not Useful

A doubled losartan dose does not meaningfully increase BP effect (receptor saturation limits) but does raise the risk of transient symptomatic hypotension. Skip the missed dose and resume schedule.

🚩 BOXED WARNING — PREGNANCY

• Second and third trimester exposure is directly toxic to the foetus
• Foetal effects: renal failure, oligohydramnios, pulmonary hypoplasia, skull hypoplasia
• Neonatal effects: hypotension, hyperkalaemia, renal failure, death
• Discontinue immediately when pregnancy is detected or confirmed
• Do not initiate in a patient planning pregnancy

👩‍⚕️ If Pregnancy Is Being Planned

• Do not wait for a positive test to switch. Switch before conception attempts begin.
• Preferred pregnancy antihypertensives: methyldopa, labetalol, nifedipine slow-release
• Diabetic nephropathy: discuss with nephrology; balance foetal risk against maternal renal decline
• Effective contraception essential while continuing losartan in reproductive-age women

Breastfeeding

Losartan and E-3174 excretion into breast milk in humans is not fully characterised. Manufacturer advises avoidance during breastfeeding. Preferred alternatives if BP control needed post-partum in a breastfeeding mother: labetalol, nifedipine, enalapril or captopril (established lactation safety).

👵 Losartan in the Older Adult

• Starting dose: 25 mg once daily commonly used
• Titration interval: 4-6 weeks rather than 2-4
• Home BP monitoring particularly valuable — white-coat effect common in elderly
• Watch orthostatic drop: measure BP standing at each visit; ask about morning dizziness
• Reduced eGFR common — monitor potassium and creatinine more often

Falls Risk Balance

Aggressive BP lowering in frail elderly can precipitate falls. Any patient with new falls, dizziness, or unsteadiness on losartan warrants assessment of standing BP and consideration of dose reduction. The trade-off is individual: cardiovascular event prevention benefit versus fall/fracture risk.

Losartan in the LIFE Elderly Subgroup

LIFE included patients up to 74 years old at randomisation. In the elderly subgroup, losartan retained its stroke-reduction advantage over atenolol. This supports losartan as a reasonable ARB choice in older patients with hypertension and LVH.

Renal Impairment

Hepatic Impairment

The Prodrug Consideration in Liver Disease

Losartan is a prodrug requiring hepatic CYP2C9 conversion to E-3174. In severe liver disease, less E-3174 is formed — but parent losartan accumulates. Net BP effect is unpredictable. Non-prodrug ARBs (irbesartan, olmesartan, telmisartan) are more straightforward in severe hepatic impairment.

🧪 The URAT1 Mechanism Recap

Losartan (the parent drug, not E-3174) inhibits URAT1, the urate/anion exchanger in the renal proximal tubule that reabsorbs filtered urate. Inhibition means more urate excreted in urine, less retained in serum. Typical magnitude: 0.5-1.0 mg/dL serum urate reduction — modest but useful, particularly when added to allopurinol or febuxostat.

The effect is losartan-specific among ARBs. Other ARBs (irbesartan, candesartan, olmesartan, valsartan) do not lower urate. Some, and thiazide diuretics, raise it.

✅ Ideal Losartan Candidate Profile

• Hypertension with a history of gout — losartan neither triggers flares nor raises urate
• Hypertension with asymptomatic hyperuricaemia in a patient with cardiovascular risk factors
• Hypertension needing add-on to a thiazide — losartan offsets some of the thiazide urate rise
• Post-transplant hypertension on cyclosporin (raises urate) — losartan mitigates

Practical Caveats

Losartan is not a gout treatment on its own. Established gout still requires proper urate-lowering therapy (allopurinol or febuxostat) to target serum urate below 6.0 mg/dL (or below 5.0 in tophaceous disease). Losartan is a favourable co-prescription, not a substitute. Do not stop allopurinol because a patient is on losartan.

🛑 ABSOLUTE CONTRAINDICATIONS

• Pregnancy (any trimester) or planning pregnancy without switching first
• Known hypersensitivity to losartan or excipients
• Prior angioedema on any ARB
• Bilateral renal artery stenosis (or single kidney with unilateral stenosis)
• Concurrent aliskiren in diabetic patients or in patients with eGFR under 60
• Severe hepatic impairment (not recommended)

⚠️ RELATIVE CONTRAINDICATIONS / CAUTIONS

• Prior ACE inhibitor angioedema — 3-10% cross-reactivity
• Baseline potassium above 5.5 mmol/L — correct or address before starting
• Severe aortic stenosis — preload-dependent state
• Concurrent chronic NSAID plus diuretic (triple whammy) — nephrotoxic combination
• Volume depletion, dehydration, active gastroenteritis — correct volume first
• Severe hyponatraemia — correct first

The Dual RAAS Blockade Rule

Losartan with an ACE inhibitor, or losartan with aliskiren, is no longer routinely recommended. Trial evidence (ONTARGET, ALTITUDE) showed net harm from more hyperkalaemia, more syncope, more acute kidney injury without cardiovascular benefit. Exceptions exist under specialist care in refractory heart failure or proteinuric renal disease.

🔄 Reasons to Switch Between Losartan and Another ARB

• Inadequate BP control on losartan 100 mg or 50 mg BID — switch to a longer-half-life ARB
• Cost pressure — switch from newer ARB to losartan
• Gout / hyperuricaemia develops on another ARB — switch to losartan
• Suspected CYP2C9 poor metaboliser on losartan — switch to non-prodrug ARB
• Trial-specific evidence — switch to a trial-validated ARB (candesartan for HFrEF, telmisartan for high CV risk, olmesartan for LVH regression)

Approximate Switch Doses (BP effect)

Practical Switching Between ARBs

No washout needed. Take last dose of current ARB, then start the new ARB at the equivalent dose the next day. Monitor BP at home for 2-3 weeks and potassium/creatinine at 2 weeks. Switches within class rarely produce clinically significant differences in BP but individual variability exists.

✅ No Rebound Syndrome

Losartan can be stopped abruptly. There is no rebound tachycardia, no rebound hypertension surge, no withdrawal symptoms. This makes it convenient when a switch is needed or the drug must be paused for a medical procedure.

Legitimate Reasons to Stop or Pause Losartan

• Pregnancy confirmed — stop immediately
• Angioedema — stop and never restart any ARB
• Severe hyperkalaemia — hold, correct, reassess
• Acute kidney injury (creatinine rise over 30%) — hold, investigate, resume if reversible
• Volume-depleting illness (severe gastroenteritis with hypotension) — sick day rule pause
• Symptomatic hypotension — dose reduction preferred over stopping

Sick Day Rules

During episodes of severe vomiting or diarrhoea with dehydration risk, temporary pause of losartan is reasonable (along with any diuretic, NSAID, metformin, SGLT2 inhibitor) until fluid intake is restored. Resume when normal eating and drinking are back for 24 hours.

📦 Storage Conditions

Not the Bathroom Cabinet

The bathroom medicine cabinet is a poor storage location for daily-use medications: humidity from showers and temperature swings accelerate degradation. A bedroom drawer or kitchen cupboard away from the stove is better. A pillbox is fine short-term (a week at a time) but return the main supply to its original container.

Disposal of Unused Tablets

Do not flush unused losartan down the toilet (environmental burden) and do not put it in household rubbish accessible to children or animals. Local pharmacy take-back schemes are the recommended route in most jurisdictions.

✈️ Travel Checklist

1. Pack in carry-on — checked baggage temperature extremes and loss risk
2. Keep in original packaging — simplifies customs and pharmacy verification abroad
3. Bring 3-5 extra days supply — flight delays, extended trips
4. Carry a prescription copy or letter naming losartan and dose
5. Note the generic name (losartan) — brand names differ by country
6. Time zone shift over 6 hours — adjust dose time by 1-2 hours per day rather than all at once

Illness Abroad

If travellers diarrhoea or vomiting produces significant dehydration on losartan, temporary pause and fluid replacement is safer than continuing. Resume when normal fluid intake is back for 24 hours. Persistent gastroenteritis warrants local medical review.

Hot Climates and Altitude

Hot climates or high altitude can amplify losartan's BP-lowering effect through vasodilation and volume shifts. Increased attention to hydration, avoidance of alcohol excess, and awareness of dizziness on standing all help. High altitude also affects RAAS activity; a scheduled home BP check on arrival at altitude is worthwhile.

📋 Annual Losartan Review Checklist

• Home BP data review — 2 weeks of morning + evening readings
• Standing BP check at visit — screen orthostatic drop
• Bloods: potassium, sodium, creatinine, eGFR, uric acid
• Urine ACR — particularly in diabetic patients (RENAAL population)
• Weight, BMI, waist circumference — total CV risk context
• Lifestyle review: salt intake, alcohol, physical activity, tobacco
• Adherence check: missed doses per week, side effects, cost pressure
• Drug interaction review: new NSAIDs, potassium salt substitutes, spironolactone, cotrimoxazole
• Contraception status in women of reproductive age
• Global CV risk recalculation — ASCVD, QRISK, SCORE2 as appropriate

Annual Decision Points

• Uncontrolled BP on losartan 100 mg / 50 mg BID — switch to longer-half-life ARB, add second agent, or investigate secondary causes
• New diabetes with albuminuria — confirm losartan 100 mg target (RENAAL evidence)
• New HFrEF — consider switch to sacubitril/valsartan (ARNI) or evidence-based ARB (candesartan, valsartan)
• Rising uric acid despite losartan — consider co-morbidities and lifestyle factors; formal urate-lowering may still be needed
• Progressive CKD — nephrology referral if eGFR decline over 5 mL/min/year or urine ACR over 70

Losartan for the Long Haul

Losartan is a lifelong medication for most patients who start it. The evidence base for continued benefit — stroke reduction, cardiovascular event reduction, delayed renal progression, protection against uric-acid-related events — extends year on year. Structured annual review keeps the prescription aligned with the patient in front of you, not the patient they were when you started.